{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:55:05Z","timestamp":1789419305153,"version":"build-2803163510"},"reference-count":141,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lysosomal storage diseases (LSD) comprise a rare and heterogeneous group of nearly 50 heritable metabolic disorders caused by mutations in proteins critical for cellular lysosomal function. Defects in the activity of these proteins in multiple organs leads to progressive intra\u2010lysosomal accumulation of specific substrates, resulting in disruption of cellular functions, extracellular inflammatory responses, tissue damage and organ dysfunction. The classification and clinical presentation of different LSD are dependent on the type of accumulated substrate. Some clinical signs and symptoms are common across multiple LSD, while others are more specific to a particular syndrome. Due to the rarity and wide clinical diversity of LSD, identification and diagnosis can be challenging, and in many cases diagnosis is delayed for months or years. Treatments, such as enzyme replacement therapy, haemopoietic stem cell transplantation and substrate reduction therapy, are now available for some of the LSD. For maximum effect, therapy must be initiated prior to the occurrence of irreversible tissue damage, highlighting the importance of prompt diagnosis. Herein, we discuss the clinical presentation, diagnosis and treatment of four of the treatable LSD: Gaucher disease, Fabry disease, Pompe disease, and two of the mucopolysaccharidoses (I and II). For each disease, we present illustrative case studies to help increase awareness of their clinical presentation and possible treatment outcomes.<\/jats:p>","DOI":"10.1111\/imj.15100","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:03:08Z","timestamp":1605758588000},"page":"5-27","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatable lysosomal storage diseases in the advent of disease\u2010specific therapy"],"prefix":"10.1111","volume":"50","author":[{"given":"Heidi","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine Royal Children's Hospital  Melbourne Victoria Australia"},{"name":"Department of Paediatrics University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Ellaway","sequence":"additional","affiliation":[{"name":"Genetic Metabolic Disorders Service Sydney Children's Hospital Network  Sydney New South Wales Australia"},{"name":"The Disciplines of Child and Adolescent Health and Genomic Medicine University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Department of Nephrology Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Reardon","sequence":"additional","affiliation":[{"name":"Department of Neurology St Vincent's Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[{"name":"Clinical Haematology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Clinical Haematology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Medicine University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"e_1_2_6_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.01.049"},{"key":"e_1_2_6_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2011.05.006"},{"key":"e_1_2_6_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318211a7e1"},{"key":"e_1_2_6_2_5_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17925\/EOR.2009.02.01.1b","article-title":"Clinical presentations of treatable lysosomal storage disorders \u2013 Gaucher, Fabry and Pompe disease and mucopolysaccharidosis I","volume":"2","author":"Graham S","year":"2009","journal-title":"Eur Ophth Rev"},{"key":"e_1_2_6_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_6_2_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0662-9"},{"key":"e_1_2_6_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510198"},{"key":"e_1_2_6_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.200900036"},{"key":"e_1_2_6_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273151"},{"key":"e_1_2_6_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.459"},{"key":"e_1_2_6_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/302757"},{"key":"e_1_2_6_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.008"},{"key":"e_1_2_6_3_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17925\/EOR.2009.02.01.1b","article-title":"Clinical presentations of treatable lysosomal storage disorders \u2013 Gaucher, Fabry and Pompe disease and mucopolysaccharidosis I","volume":"2","author":"Graham S","year":"2009","journal-title":"Eur Ophth Rev"},{"key":"e_1_2_6_3_5_2","article-title":"Glucocerebrosidase: functions in and beyond the lysosome","volume":"9","author":"Boer DEC","year":"2020","journal-title":"J Clin Med"},{"key":"e_1_2_6_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.12.001"},{"key":"e_1_2_6_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_6_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004399900075"},{"key":"e_1_2_6_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14156"},{"key":"e_1_2_6_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318211a7e1"},{"key":"e_1_2_6_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1362-0"},{"key":"e_1_2_6_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.08.002"},{"key":"e_1_2_6_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15402"},{"key":"e_1_2_6_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2005.04.005"},{"key":"e_1_2_6_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2018.1445524"},{"key":"e_1_2_6_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1771-z"},{"key":"e_1_2_6_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352971"},{"key":"e_1_2_6_3_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273151"},{"key":"e_1_2_6_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.05.005"},{"key":"e_1_2_6_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242104"},{"key":"e_1_2_6_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01150-6"},{"key":"e_1_2_6_3_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268649"},{"key":"e_1_2_6_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23381"},{"key":"e_1_2_6_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23383"},{"key":"e_1_2_6_3_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-366955"},{"key":"e_1_2_6_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24801"},{"key":"e_1_2_6_3_27_2","first-page":"CD010324","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","author":"Shemesh E","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1779"},{"key":"e_1_2_6_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61841-9"},{"key":"e_1_2_6_3_30_2","unstructured":"Sanofi\u2010Aventis Australia Pty Ltd. Cerdelga Product Information [cited 2020 Aug 11]. Available from URL:https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-eliglustat-150818-pi.pdf"},{"key":"e_1_2_6_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.459"},{"key":"e_1_2_6_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318211a7e1"},{"key":"e_1_2_6_4_3_2","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.66.s1.10"},{"key":"e_1_2_6_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30"},{"key":"e_1_2_6_4_5_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17925\/EOR.2009.02.01.1b","article-title":"Clinical presentations of treatable lysosomal storage disorders \u2010 Gaucher, Fabry and Pompe disease and Mucopolysaccharidosis I","volume":"2","author":"Graham S","year":"2009","journal-title":"Eur Ophth Rev"},{"key":"e_1_2_6_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0521-2"},{"key":"e_1_2_6_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_6_4_8_2","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318183f132"},{"key":"e_1_2_6_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000237866.70357.c6"},{"key":"e_1_2_6_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004399900075"},{"key":"e_1_2_6_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.11.750"},{"key":"e_1_2_6_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.tb02386.x"},{"key":"e_1_2_6_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.10.007"},{"key":"e_1_2_6_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bb05bb"},{"key":"e_1_2_6_4_15_2","volume-title":"Fabry Disease: Perspectives from 5\u2009Years of FOS","author":"Sunder\u2010Plassmann G","year":"2006"},{"key":"e_1_2_6_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67635-0"},{"key":"e_1_2_6_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.014"},{"key":"e_1_2_6_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"e_1_2_6_4_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"e_1_2_6_4_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/422366"},{"key":"e_1_2_6_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"e_1_2_6_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.10.009"},{"key":"e_1_2_6_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6"},{"key":"e_1_2_6_4_24_2","unstructured":"Australian Government Department of Health.Life Saving Drugs Program (LSDP) guidelines for initial application and annual reapplication for subsidised treatment for Fabry disease[cited 2020 Aug 2]. Available from URL:https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/79DD3FACA8E75AE2CA257BF0001BAF7A\/$File\/Fabry-disease-Guidelines.pdf"},{"key":"e_1_2_6_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510198"},{"key":"e_1_2_6_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-104178"},{"key":"e_1_2_6_4_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168346"},{"key":"e_1_2_6_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12542"},{"key":"e_1_2_6_4_29_2","volume-title":"Fabry Disease: Perspectives from 5\u2009Years of FOS","author":"Keilmann A","year":"2006"},{"key":"e_1_2_6_4_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.526293"},{"key":"e_1_2_6_4_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.63.10_suppl_4.S24"},{"key":"e_1_2_6_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-7364-2-5-297"},{"key":"e_1_2_6_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306278"},{"key":"e_1_2_6_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.12.004"},{"key":"e_1_2_6_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.09.006"},{"key":"e_1_2_6_5_4_2","unstructured":"US National Library of Medicine National Institutes of Health.Genetics Home Reference. Pompe Disease[cited 2020 Jun 5]. Available from URL:https:\/\/ghr.nlm.nih.gov\/condition\/pompe-disease#statistics"},{"key":"e_1_2_6_5_5_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17925\/EOR.2009.02.01.1b","article-title":"Clinical presentations of treatable lysosomal storage disorders \u2013 Gaucher, Fabry and Pompe Disease and Mucopolysaccharidosis I","volume":"2","author":"Graham S","year":"2009","journal-title":"Eur Ophth Rev"},{"key":"e_1_2_6_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165979.46537.56"},{"key":"e_1_2_6_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"e_1_2_6_5_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198776.53007.2c"},{"key":"e_1_2_6_5_9_2","first-page":"304","article-title":"Over idiopathische hypertrofie van het hart","volume":"76","author":"Pompe JC","year":"1932","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0922-9"},{"key":"e_1_2_6_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318211a7e1"},{"key":"e_1_2_6_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2015.04.006"},{"key":"e_1_2_6_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004399900075"},{"key":"e_1_2_6_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_6_5_15_2","unstructured":"KishnaniP BergerK CarterGT CaseLE. Late\u2010onset Pompe disease: Presentation diagnosis and management. A CME monograph [cited 2020 Jun 11]. Available from URL:https:\/\/www.aanem.org\/mxonline\/resources\/downloads\/products\/ED01.pdf"},{"key":"e_1_2_6_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000154301.76619.5C"},{"key":"e_1_2_6_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.03.007"},{"key":"e_1_2_6_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0442-y"},{"key":"e_1_2_6_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh384"},{"key":"e_1_2_6_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.12.009"},{"key":"e_1_2_6_5_21_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano A","year":"2019","journal-title":"Ann Transl Med"},{"key":"e_1_2_6_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61555-X"},{"key":"e_1_2_6_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21025"},{"key":"e_1_2_6_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.02.013"},{"key":"e_1_2_6_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.07.014"},{"key":"e_1_2_6_5_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamaneurol.486"},{"key":"e_1_2_6_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21376"},{"key":"e_1_2_6_5_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004711"},{"key":"e_1_2_6_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00125817-200103000-00008"},{"key":"e_1_2_6_5_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"e_1_2_6_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02533-2"},{"key":"e_1_2_6_5_32_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.5.e448"},{"key":"e_1_2_6_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.10.009"},{"key":"e_1_2_6_5_34_2","unstructured":"Myozyme\u00ae (alglucosidase alfa) summary of product characteristics. Genzyme Corporation. Available from URL:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myozymeAccessed 21 Oct 2020."},{"key":"e_1_2_6_5_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-73"},{"key":"e_1_2_6_5_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-49"},{"key":"e_1_2_6_5_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6636-x"},{"key":"e_1_2_6_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31319"},{"key":"e_1_2_6_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.08.003"},{"key":"e_1_2_6_5_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067052"},{"key":"e_1_2_6_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2011.05.006"},{"key":"e_1_2_6_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker394"},{"key":"e_1_2_6_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_6_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004399900075"},{"key":"e_1_2_6_6_6_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino D","year":"2018","journal-title":"Ital J Pediatr"},{"key":"e_1_2_6_6_7_2","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D'Avanzo F","year":"2020","journal-title":"Int J Mol Sci"},{"key":"e_1_2_6_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0662-9"},{"key":"e_1_2_6_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318211a7e1"},{"key":"e_1_2_6_6_10_2","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I","volume":"6","author":"Jameson E","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_11_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17925\/EOR.2009.02.01.1b","article-title":"Clinical presentations of treatable lysosomal storage disorders \u2013 Gaucher, Fabry and Pompe Disease and Mucopolysaccharidosis I","volume":"2","author":"Graham S","year":"2009","journal-title":"Eur Ophth Rev"},{"key":"e_1_2_6_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.20314"},{"key":"e_1_2_6_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.01.011"},{"key":"e_1_2_6_6_14_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13052-018-0550-5","article-title":"Mucopolysaccharidoses: early diagnostic signs in infants and children","volume":"44","author":"Galimberti C","year":"2018","journal-title":"Ital J Pediatr"},{"key":"e_1_2_6_6_15_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2156"},{"key":"e_1_2_6_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.01.046"},{"key":"e_1_2_6_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101183440304"},{"key":"e_1_2_6_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.08.007"},{"key":"e_1_2_6_6_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184065"},{"key":"e_1_2_6_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608075"},{"key":"e_1_2_6_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-0112-z"},{"key":"e_1_2_6_6_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1274"},{"key":"e_1_2_6_6_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0999"},{"key":"e_1_2_6_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.09.001"},{"key":"e_1_2_6_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000232477.37660.fb"},{"key":"e_1_2_6_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-42"},{"key":"e_1_2_6_6_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0712-3"},{"key":"e_1_2_6_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.11.041"},{"key":"e_1_2_6_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.06.020"},{"key":"e_1_2_6_6_30_2","first-page":"1","article-title":"Hematopoietic stem cell transplantation in mucopolysaccharidosis type II: a literature review and critical analysis","volume":"6","author":"Barth AL","year":"2018","journal-title":"J Inborn Errors Metab"},{"key":"e_1_2_6_6_31_2","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10010046","article-title":"Assessment of activity of daily life in mucopolysaccharidosis type II patients with hematopoietic stem cell transplantation","volume":"10","author":"Suzuki Y","year":"2020","journal-title":"Diagnostics"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.15100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T20:31:55Z","timestamp":1693859515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.15100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":141,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/imj.15100"],"URL":"https:\/\/doi.org\/10.1111\/imj.15100","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}